NTX AV02
Alternative Names: NTX-AV02Latest Information Update: 16 Nov 2023
At a glance
- Originator noctuRNA Therapeutics
- Class Antivirals; Circular RNA
- Mechanism of Action Viral RNA degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis C
Most Recent Events
- 15 Nov 2023 NoctuRNA Therapeutics has patent protection for RNA-based drug platform in an undisclosed location (noctuRNA Therapeutics website, November 2023)
- 15 Nov 2023 Preclinical trials in Hepatitis C in Spain (Parenteral) prior to November 2023 (noctuRNA Therapeutics pipeline, November 2023)
- 01 Nov 2023 Pharmacodynamics data from in-vitro studies in hepatitis C released by noctuRNA Therapeutics